ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025 (Fiscal Q2 2025). Arrowhead Pharmaceuticals is a biopharmaceutical company developing RNA interference (RNAi) therapeutics to treat intractable diseases. The company operates research facilities in California and Wisconsin and maintains a pipeline of candidates in cardiometabolic, pulmonary, liver, neuromuscular, and CNS therapeutic areas.

Key Financial Metrics

Note: Total liquidity includes $185.7 million in cash/cash equivalents and $911.7 million in available-for-sale securities. Debt includes $65.0 million current and $208.9 million long-term.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased from $0 in the prior year quarter to $542.7 million, driven almost entirely by the Sarepta Collaboration Agreement. Six-month revenue rose from $3.6 million to $545.2 million.
• Profitability Shift: The company swung from a net loss of $125.3 million (Q2 2024) to a net income of $370.4 million (Q2 2025). This is primarily due to the recognition of upfront payments and equity premiums from the Sarepta deal.
• Expense Growth: Research and Development (R&D) expenses increased 32% year-over-year to $133.1 million for the quarter, driven by higher candidate costs as the pipeline advances. General and Administrative (G&A) expenses rose 13% to $28.4 million.
• Balance Sheet Strengthening: Total assets grew from $1.14 billion to $1.57 billion. Stockholders' equity increased significantly from $185.4 million to $683.3 million due to the Sarepta equity investment and net income.

Guidance, Outlook, and Management Commentary

• Sarepta Collaboration: The company closed a global licensing and collaboration agreement with Sarepta Therapeutics. Arrowhead received a $500 million upfront payment and $325 million via a private placement of common stock. The deal includes potential milestones up to $10 billion and royalties.
• Clinical Progress:
  • Submitted a New Drug Application (NDA) for plozasiran (hypertriglyceridemia) with a PDUFA date of November 18, 2025.
  • ARO-C3 and ARO-CFB showed promising interim results in complement-mediated diseases.
  • ARO-ALK7 received regulatory clearance for a Phase 1/2a trial in New Zealand.
• Liquidity Outlook: Management expects sufficient liquidity to fund operations for at least the next 12 months. The company utilized proceeds from the Sarepta deal to repay $150 million of its credit facility.
• Debt Structure: The company maintains a $500 million senior secured term loan (Credit Facility) with a 15% interest rate (paid in kind). A portion of the Sarepta upfront payment was used to reduce this debt.

Investor Verification Checklist

• Revenue Recognition Timing: Verify the specific accounting treatment and future recognition schedule for the $904.9 million total transaction price allocated from the Sarepta agreement, particularly the portion recognized over time for R&D services.
• Debt Covenants: Review the Credit Facility covenants, specifically the liquidity maintenance requirement ($100 million) and the "2x on invested capital" payment trigger if the loan is repaid before August 2028.
• Royalty Liability Amortization: Monitor the "Liability related to the sale of future royalties" ($352.3 million) and the assumptions used for the effective interest rate (currently 6.3%) regarding the Royalty Pharma agreement.
• Regulatory Timeline: Confirm the status of the plozasiran NDA review and the potential for an advisory committee meeting, as the FDA currently indicates none is planned.
• Executive Compensation: Note the recent Severance and Change of Control agreements filed for key executives (CEO, CFO, CMO) and the CFO's planned retirement transition.